The addition is expected to accelerate Labcorp’s liquid biopsy capabilities and expand its oncology portfolio of next-generation sequencing-based genomic profiling capabilities, the company said February 21.
The acquisition was announced Dec. 23.
The addition is expected to accelerate Labcorp’s liquid biopsy capabilities and expand its oncology portfolio of next-generation sequencing-based genomic profiling capabilities, the company said February 21.
The acquisition was announced Dec. 23.
